Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
AssigneedeCODE Genetics ehf.
InventorHakon Hakonarson
Life of this patent
Estimating the term…
Abstract
Methods are disclosed for predicting the efficacy of a drug for treating an inflammatory disease in a human patient, including: obtaining a sample of cells from the patient; obtaining a gene expression profile of the sample in the absence and presence of in vitro modulation of the cells with specific cytokines and/or mediators; and comparing the gene expression profile of the sample with a reference gene expression profile, wherein similarities between the sample expression profile and the reference expression profile predicts the efficacy of the drug for treating the inflammatory disease in the patient.
Claims18
A method for predicting the efficacy of a drug for treating an inflammatory disease in a human patient, comprising:
- a) obtaining a sample of cells from the patient;
- b) obtaining a gene expression profile from the sample in the absence and presence of in vitro modulation of the cells with specific cytokines/mediators;
- and
- c) comparing the gene expression profile of the sample with a reference gene expression profile, wherein similarity between the sample expression profile and the reference expression profile predicts the efficacy of the drug for treating the inflammatory disease in the patient.
A method of screening for glucocorticoid sensitivity in an asthmatic patient comprising:
- a) obtaining a sample of cells from the patient;
- b) obtaining a gene expression profile from the sample in the absence and presence of in vitro activation of the cells with specific cytokines/mediators;
- and
- c) comparing the gene expression profile of the sample with a reference gene expression profile,
- wherein similarity in expression profiles between the sample and reference profiles indicates glucocorticoid sensitivity in the patient from whom the sample was obtained.
A method for predicting efficacy in a human asthmatic patient of leukotriene antagonists, comprising:
- a) obtaining a sample of cells from the patient;
- b) obtaining a gene expression profile from the sample in the absence and presence of in vitro modulation of the cells with specific cytokines/mediators;
- and
- c) comparing the gene expression profile of the sample with a reference gene expression profile,
- wherein similarity in expression profiles between the sample and reference profiles predicts the efficacy in the human asthmatic patient of leukotriene antagonists.
An expression profile comprising expression levels of gene products from one or more genes described in Tables 1, 2A and 2B.
Dependencies are inferred from the claim text.